Mineralys Therapeutics Inc. Common Stock Earnings Recaps
Q2 2025
Aug 13, 2025
Mineralys Therapeutics reported strong clinical trial results for lorundrostat, positioning it as a promising treatment for uncontrolled hypertension and related conditions, with significant interest from healthcare providers for future prescriptions.
Key takeaways
- Pivotal trial data from the Launch-HTN and Advance-HTN studies demonstrated significant reductions in systolic blood pressure, published in major medical journals.
- A survey indicated that 95% of surveyed cardiologists and primary care physicians are likely to prescribe lorundrostat for patients with resistant hypertension if approved.
- The company is actively preparing for a pre-NDA meeting with the FDA in Q4 2025, signaling readiness for regulatory submission.
- Lorundrostat shows potential benefits in patients with comorbidities such as chronic kidney disease and obstructive sleep apnea, broadening its market application.
- Ongoing pre-commercial efforts include enhancing market access and payer value assessments to support lorundrostat's launch.